Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammad Hussain

Neurology Jefferson City, TN Medical Doctor

NPI 1699773747 CMS profile 348831

657 E Broadway Blvd Ste C, Jefferson City, TN 37760

Open in the dashboard

General payments

$18,888

1,019 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mohammad Hussain of Jefferson City, TN is reported in the CMS Open Payments database as having received $18,888 across 1,019 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,906 134
2024 General $3,073 158
2023 General $1,637 100
2022 General $1,695 126
2021 General $2,707 184
2020 General $3,404 154
2019 General $3,466 163

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammad Hussain
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Mohammad Hussain were reported at $2,906. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Mohammad Hussain Neurology median Middle half National median
2019 $3,466 $474 $118–$2,177 $163
2020 $3,404 $367 $82–$2,309 $114
2021 $2,707 $438 $104–$2,547 $132
2022 $1,695 $442 $103–$2,388 $149
2023 $1,637 $464 $119–$2,312 $160
2024 $3,073 $468 $119–$2,323 $164
2025 $2,906 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. UCB, Inc. $2,221 112 payments
  2. Biogen, Inc. $1,465 97 payments
  3. LivaNova USA, Inc. $1,312 14 payments
  4. Neurelis, Inc. $1,167 67 payments
  5. Novartis Pharmaceuticals Corporation $1,155 80 payments
  6. AbbVie, Inc. $1,138 107 payments
  7. Alexion Pharmaceuticals, Inc. $937 46 payments
  8. MicroVention, Inc. $892 4 payments
  9. Lundbeck LLC $830 44 payments
  10. Eisai Inc. $809 57 payments
  11. Other $6,962 391 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,186 1,005 payments
  2. Travel and Lodging $1,584 6 payments
  3. Education $118 8 payments
Products named General payments · program years 2019–2025
  1. VNS Therapy $1,210 12 payments
  2. Briviact $1,190 58 payments
  3. VALTOCO $1,167 67 payments
  4. WEB $892 4 payments
  5. UBRELVY $845 80 payments
  6. TYSABRI $671 41 payments
  7. AIMOVIG $643 39 payments
  8. Fycompa $560 44 payments
  9. QULIPTA $555 43 payments
  10. ULTOMIRIS $502 22 payments
  11. Other $12,230 721 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 84 drugs

Part D claims

5,622

Median for Neurology: 833

Drug cost

$4,766,931

Median for Neurology: $202,670

Branded share of claims

34.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Soliris Eculizumab Brand 17 $949,014
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 27 $705,806
Ocrevus Ocrelizumab Brand 15 $608,486
Kesimpta Pen Ofatumumab Brand 54 $482,355
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 34 $409,907
Zeposia Ozanimod Hydrochloride Brand 22 $216,868
Nurtec Odt Rimegepant Sulfate Brand 92 $147,351
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 12 $123,219
Qulipta Atogepant Brand 98 $110,236
Tysabri Natalizumab Brand 13 $107,271

The 10 drugs with the highest cost, of 84 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$62,785

Of which drugs: $733

Medicare patients

190

Average age 65

Services billed

1,801

119 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Depression 39%
Diabetes 35%
COPD 29%
Chronic kidney disease 25%
Alzheimer's or dementia 25%
Ischemic heart disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml A9579 Office 31 585 $690

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
$394 — —
Briviact
$283 35 —
INGREZZA
$235 — —
VALTOCO
$235 11 —
KESIMPTA
$223 54 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,019 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record